...
首页> 外文期刊>BMC Cancer >Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort
【24h】

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort

机译:与乳腺癌风险相关的类固醇激素受体共激活因子和共抑制因子基因常见编码变异的筛选和关联测试:多族裔队列

获取原文
           

摘要

Background Only a limited number of studies have performed comprehensive investigations of coding variation in relation to breast cancer risk. Given the established role of estrogens in breast cancer, we hypothesized that coding variation in steroid receptor coactivator and corepressor genes may alter inter-individual response to estrogen and serve as markers of breast cancer risk. Methods We sequenced the coding exons of 17 genes ( EP300, CCND1, NME1, NCOA1, NCOA2, NCOA3, SMARCA4, SMARCA2, CARM1, FOXA1, MPG, NCOR1, NCOR2, CALCOCO1, PRMT1, PPARBP and CREBBP ) suggested to influence transcriptional activation by steroid hormone receptors in a multiethnic panel of women with advanced breast cancer (n = 95): African Americans, Latinos, Japanese, Native Hawaiians and European Americans. Association testing of validated coding variants was conducted in a breast cancer case-control study (1,612 invasive cases and 1,961 controls) nested in the Multiethnic Cohort. We used logistic regression to estimate odds ratios for allelic effects in ethnic-pooled analyses as well as in subgroups defined by disease stage and steroid hormone receptor status. We also investigated effect modification by established breast cancer risk factors that are associated with steroid hormone exposure. Results We identified 45 coding variants with frequencies ≥ 1% in any one ethnic group (43 non-synonymous variants). We observed nominally significant positive associations with two coding variants in ethnic-pooled analyses ( NCOR2 : His52Arg, OR = 1.79; 95% CI, 1.05–3.05; CALCOCO1 : Arg12His, OR = 2.29; 95% CI, 1.00–5.26). A small number of variants were associated with risk in disease subgroup analyses and we observed no strong evidence of effect modification by breast cancer risk factors. Based on the large number of statistical tests conducted in this study, the nominally significant associations that we observed may be due to chance, and will need to be confirmed in other studies. Conclusion Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population. Cataloging and testing of coding variants in coactivator and corepressor genes should continue and may serve as a valuable resource for investigations of other hormone-related phenotypes, such as inter-individual response to hormonal therapies used for cancer treatment and prevention.
机译:背景技术仅有限的研究对与乳腺癌风险有关的编码变异进行了全面的研究。鉴于雌激素在乳腺癌中已确立的作用,我们假设类固醇受体共激活因子和共加压因子基因的编码变异可能会改变个体对雌激素的反应,并可能成为乳腺癌风险的标志。方法我们对17个基因的编码外显子进行了测序(EP300,CCND1,NME1,NCOA1,NCOA2,NCOA3,SMARCA4,SMARCA2,CARM1,FOXA1,MPG,NCOR1,NCOR2,CALCOCO1,PRMT1,PPARBP和CREBBP),这些基因可能通过影响转录激活多种类型的晚期乳腺癌妇女(n = 95)中的类固醇激素受体:非裔美国人,拉丁裔,日本人,夏威夷原住民和欧洲裔美国人。在多种族队列中嵌套的乳腺癌病例对照研究(1,612例侵入性病例和1,961例对照)中进行了经过验证的编码变体的关联测试。我们使用逻辑回归来估计在族裔合并分析以及由疾病阶段和类固醇激素受体状态定义的亚组中等位基因效应的比值比。我们还研究了与类固醇激素暴露相关的已确定的乳腺癌危险因素对效果的改善。结果我们在任何一个族群中识别了频率≥1%的45个编码变体(43个非同义变体)。在族群分析中,我们观察到名义上显着的正相关性,具有两个编码变体(NCOR2:His52Arg,OR = 1.79; 95%CI,1.05-3.05; CALCOCO1:Arg12His,OR = 2.29; 95%CI,1.00–5.26)。少数亚型与疾病亚组分析中的风险相关,我们没有观察到有强有力的证据证明乳腺癌危险因素会影响疗效。基于本研究中进行的大量统计检验,我们观察到的名义上显着的关联可能是偶然的缘故,需要在其他研究中进行确认。结论我们的发现表明,这些候选基因的共同编码变异对普通人群的乳腺癌风险没有实质性贡献。共激活因子和共抑制因子基因中编码变体的分类和测试应继续进行,并可以作为研究其他激素相关表型的宝贵资源,例如对用于癌症治疗和预防的激素疗法的个体间反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号